Analyzing Cardiome Pharma Corporation (CRME) & KalVista Pharmaceuticals (KALV)
Cardiome Pharma Corporation (NASDAQ: CRME) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
This is a summary of recent recommendations for Cardiome Pharma Corporation and KalVista Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cardiome Pharma Corporation||0||1||4||0||2.80|
Cardiome Pharma Corporation currently has a consensus price target of $6.56, suggesting a potential upside of 202.42%. KalVista Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 157.14%. Given Cardiome Pharma Corporation’s higher probable upside, analysts clearly believe Cardiome Pharma Corporation is more favorable than KalVista Pharmaceuticals.
Insider & Institutional Ownership
55.1% of Cardiome Pharma Corporation shares are owned by institutional investors. Comparatively, 75.7% of KalVista Pharmaceuticals shares are owned by institutional investors. 49.1% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Cardiome Pharma Corporation has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.
This table compares Cardiome Pharma Corporation and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cardiome Pharma Corporation||-110.95%||-78.51%||-38.30%|
Earnings & Valuation
This table compares Cardiome Pharma Corporation and KalVista Pharmaceuticals’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Cardiome Pharma Corporation||$23.21 million||3.16||-$17.41 million||($0.83)||-2.61|
|KalVista Pharmaceuticals||$1.50 million||45.33||-$15.90 million||N/A||N/A|
KalVista Pharmaceuticals has higher revenue, but lower earnings than Cardiome Pharma Corporation.
KalVista Pharmaceuticals beats Cardiome Pharma Corporation on 7 of the 12 factors compared between the two stocks.
About Cardiome Pharma Corporation
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.
About KalVista Pharmaceuticals
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Receive News & Ratings for Cardiome Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.